SHORT REPORT

Cutaneous reactions to COVID-19 vaccine at the dermatology primary care

Martina Burlando | Astrid Herzum | Claudia Micalizzi | Emanuele Cozzani | Aurora Parodi

Department of Health Sciences (DISSAL), Section of Dermatology, San Martino Polyclinic Hospital IRCCS, Largo R, University of Genova, Genova, Italy

Correspondence
Astrid Herzum, Department of Health Sciences (DISSAL), Section of Dermatology, San Martino Polyclinic Hospital IRCCS, Largo R, University of Genova, Benzi, 10 16132 Genova Italy. Email: astridherzum@yahoo.it

Abstract
Introduction: Coronavirus disease 2019 (COVID-19) vaccines can cause adverse reactions, mainly from vaccine-induced immune responses. Some of these may also involve the skin and worry unaware patients. A better understanding of such adverse reactions may reduce concerns and help promote the vaccination of large population groups.

Methods: All the reports of patients admitted to our Dermatology Primary Care, from March 2021 to June 2021, were retrospectively examined to collect descriptive data on skin reactions arising after COVID-19 vaccination.

Results: Out of 200 vaccinated patients admitted to the Dermatology Primary Care, 21 (10.5%) referred cutaneous reactions with onset after vaccination. Only one patient required hospitalization for generalized bullous erythema multiforme, which occurred 48 h after the second vaccine dose. The other patients’ cutaneous reactions to vaccination were of mild/moderate degree. Three patients presented exacerbation of their cutaneous diseases.

Conclusions: Cutaneous reactions observed in our sample were mostly mild or moderate. Awareness must be raised to recognize and treat eventual severe reactions. Future studies are needed to assess the incidence of cutaneous reactions following COVID-19 vaccination.

Keywords
coronavirus vaccine, COVID-19 skin, COVID-19 urticaria, COVID-19 vaccination reaction, COVID-19 vaccine rash, vaccine allergy

1 INTRODUCTION

Coronavirus disease 2019 (COVID-19) vaccines are considered the most effective intervention to control the worldwide coronavirus epidemics we are nowadays confronted with. However, as for all types of drugs and vaccines, COVID-19 vaccines can cause adverse reactions, mainly from vaccine-induced immune responses. Some of these may also involve the skin, often scaring unaware patients for the eye-catching, unfamiliar presentation.
A better understanding of such adverse reactions may reduce concerns and promote the vaccination of large population groups.

For this reason, to provide a report on COVID-19 vaccine skin reactions, we collected all the patients’ reports from our Dermatology Primary care to understand which cutaneous reactions were related to vaccination.

2 MATERIALS AND METHODS

From March 2021 to June 2021 all the patients admitted for any dermatological issue at the Dermatology Primary Care, after the first aid triage, were asked for recent COVID-19 symptoms, exposures, and vaccination. All the reports were retrospectively examined to collect data on possible associations between cutaneous manifestations and COVID-19 vaccination.

3 RESULTS

Of 200 patients (116 women, 84 men) admitted to the Dermatology Primary Care, who had been vaccinated against COVID-19, 21 (10.5%) referred cutaneous reactions after COVID-19 vaccination (Table 1).

Of these, 15 (71%) were females, with a mean age of 48 years, 6 (29%) were males, with a mean age of 62 years.

Female gender was not significantly more associated to reactions to the vaccine (4%, 15/116) than male gender (7%, 6/84) (p value >.05 calculated with Fisher exact test).

BioNTech/Pfizer was the most frequently reported vaccine used (62%, 13/21).

Reactions were more frequently reported after the second dose of vaccine (57%, 12/21) and occurred from 3 h to 30 days after vaccination. One patient out of 21, after the second dose of Moderna vaccine, developed a bullous erythema multiforme, which required hospitalization (Figure 1).

Ten of 21 patients developed macular-urticarial rashes, which appeared within 24 h after the second dose of vaccine (57%, 12/21) and occurred from 3 h to 30 days after vaccination. One patient out of 21, after the second dose of Moderna vaccine, developed a bullous erythema multiforme, which required hospitalization (Figure 1).

Ten of 21 patients developed macular-urticarial rashes, which occurred from 3 h to 30 days after vaccination. One patient out of 21, after the second dose of Moderna vaccine, developed a bullous erythema multiforme, which required hospitalization (Figure 1).

Ten out of 21 developed macular-urticarial reactions (Figure 2). In 4 patients out of 10, it appeared within 24 h of vaccine, in 6 patients after 24 h. Four out of 10 patients reported headaches associated with the rash. Two out of 10 patients reported nausea; only one had dizziness. The reaction developed after the first dose of vaccine in 6 of 10 patients.3

Three out of 21 patients developed herpes zoster (HZ) 20 days after vaccination, associated with severe asthenia (Figure 3). None of the patients observed reported previous HZ. Only one patient out of 21 developed a diffuse form of pityriasis rosea of Gibert, only modestly itchy and associated with asthenia, after receiving the second dose of Pfizer vaccine.

One patient reported the appearance of orange plaques on the nose, eyebrows and cheeks 72 h after administration of the first dose of Pfizer. A biopsy was performed and a diagnosis of sarcoidosis was made. One patient experienced a flare of lichen planus plaques, 15 days after the second dose of Pfizer and one patient experienced recurrence of psoriatic plaques, 16 days after the second dose of Pfizer (Figure 4).

One patient out of 21 reported eczymosis on the third toe of the left foot, 4 days after administration of Pfizer vaccine. One patient reported eruptive angio- mas of the trunk and arms, which appeared within 24 h after the second dose of Pfizer vaccine. An 80-year-old patient claimed the appearance of a giant seborrheic keratosis within 24 h after the second dose of Pfizer vaccine.

4 DISCUSSION

Since COVID-19 vaccination is spreading, there have been numerous reports of adverse reactions to the vaccine.5-13 The fear of the vaccine in the population is not justified, since many supposed reactions to the vaccine are in fact not due to it.5,6 In our sample, only one of the 21 patients reporting skin reactions required hospitalization for generalized bullous erythema multiforme, which occurred 48 h after the second Moderna vaccine dose. Erythema multiforme is an immune-mediated mucocutaneous inflammatory condition, which has been already reported in association with COVID-19 and COVID-19 vaccination, possibly caused by vaccine components eliciting an immune dysregulation, leading to a T-lymphocyte auto-immune response directed against keratinocytes, causing cell death and dermo-epidermal junction detachment.14

Fortunately, none of the other patients developed life-threatening reactions.

Ten out of 21 developed macular or urticarial rashes, which resolved with antihistamine or spontaneously, similarly to cases reported in the literature.2-6 Two patients presented generalized pruritic rash shortly after vaccination (≤4 h), possibly representing immediate hypersensitivity type I reactions against vaccine excipients.2-6

Other rapid reactions reported were one pruritic generalized rash and a facial swelling and flushing, which occurred <24 h, but >4 h after vaccination, probably representing nonallergic (non-immunoglobulin E mediated) but pseudo-allergic reactions considering the time of occurrence.5-8

The other 6 macular-papular/urticarial reactions reported, occurred >48 h after vaccination, probably representing a delayed hypersensitivity (Coombs and Gell type IV) reactions.3-10
| Patient no | Age | Sex | Onset time from vaccination | Vaccination type | Dose no | Cutaneous manifestations | Other symptoms | Presumed COVID-19 vaccine association |
|------------|-----|-----|----------------------------|------------------|---------|--------------------------|---------------|-------------------------------------|
| 1          | 48  | F   | 3 h                        | Oxford-AstraZeneca | 2nd     | Small pruritic wheals on the upper limbs and chest | None reported | Correlated                          |
| 2          | 27  | F   | 4 h                        | BioNTech/Pfizer    | 2nd     | Generalized maculopapular pruritic rash, with erythematous patches on the knees | Headache      | Correlated                          |
| 3          | 29  | F   | 12 h                       | Oxford-AstraZeneca | 1st     | Facial swelling, flushing and erythema | Headache, nausea, asthenia | Correlated                          |
| 4          | 76  | M   | 24 h                       | Oxford-AstraZeneca | 1st     | Maculopapular with micropapules and urticarial pruritic generalized rash | Headache, fever | Correlated                          |
| 5          | 67  | M   | 48 h                       | Moderna            | 2nd     | Bullos pruritic erythema multiforme | Headache, fever, was hospitalized | Correlated                          |
| 6          | 58  | M   | 48 h                       | BioNTech/Pfizer    | 1st     | Maculopapular pruritic generalized rash | None reported | Correlated                          |
| 7          | 84  | M   | 48 h                       | BioNTech/Pfizer    | 1st     | Maculopapular pruritic generalized rash, starting from injection site | None reported | Correlated                          |
| 8          | 35  | F   | 72 h                       | Moderna            | 1st     | Maculopapular pruritic generalized rash | Nausea, dyspnea, headache, vertigins | Correlated                          |
| 9          | 27  | F   | 10 days                    | Oxford-AstraZeneca | 1st     | Macular pruritic generalized rash (especially on neck, wrists, arms) | Headache      | Correlated                          |
| 10         | 43  | F   | 10 days                    | BioNTech/Pfizer    | 1st     | Urticarial pruritic generalized rash (especially on eyelids and arms) | None reported | Correlated                          |
| 11         | 44  | F   | 15 days                    | BioNTech/Pfizer    | 1st     | Macular pruritic generalized rash with erythematous patches on the elbows | None reported | Correlated                          |
| 12         | 59  | F   | 15 days                    | BioNTech/Pfizer    | 2nd     | Lichen planus plaques on both feet and ankles | None reported | Correlated                          |
| 13         | 56  | M   | 16 days                    | BioNTech/Pfizer    | 2nd     | Psoriasis plaques on the trunk and limbs | None reported | Correlated                          |
| 14         | 53  | F   | 72 h                       | BioNTech/Pfizer    | 1st     | Cutaneous sarcoidosis of the nose, eyelids, cheek | Dyspnea and pulmonary sarcoidosis | Correlated                          |
| 15         | 58  | F   | 20 days                    | BioNTech/Pfizer    | 2nd     | Herpes Zoster, crural | Headache, asthenia | Correlated                          |
| 16         | 82  | F   | 20 days                    | BioNTech/Pfizer    | 2nd     | Herpes Zoster, cervical | Generalized arthralgia and myalgia, asthenia, local dysesthesia | Correlated                          |

(Continues)
Though initially rarely observed during clinical approval studies, these hypersensitivity reactions seem now to be a well-described phenomenon after COVID-19 vaccination.1 Indeed, McMahon et al.8 reported in a recent study delayed large local reactions as the most frequent among cutaneous findings after messenger RNA (mRNA) COVID-19 vaccinations (BioNTech/Pfizer and Moderna).

Of note, it must be considered that the rash may also represent an immune response to spike protein, as similar morbilliform eruptions that are negative for viral particles have been observed in patients with primary HZ virus reactivations.7

### TABLE 1 (Continued)

| Patient no | Age | Sex | Onset time from vaccination | Vaccination type | Dose no | Cutaneous manifestations | Other symptoms | Presumed COVID-19 vaccine association |
|------------|-----|-----|-----------------------------|------------------|--------|-------------------------|---------------|-------------------------------------|
| 17         | 37  | F   | 30 days                     | Oxford-AstraZeneca | 2nd    | Herpse Zoster, facial   | Flu-like symptoms | Correlated                          |
| 18         | 31  | M   | 30 days                     | BioNTech/Pfizer   | 2nd    | Pityriasis Rosea, diffuse, only mildly pruritic | Headache, asthenia | Correlated                          |
| 19         | 42  | F   | 4 days                      | BioNTech/Pfizer   | 2nd    | Ecchymosis on the third finger of the left foot | Headache, otalgia | Noncorrelated                       |
| 20         | 54  | F   | 24 h                        | BioNTech/Pfizer   | 2nd    | Eruptive angiomata of trunk and arms | None reported | Noncorrelated                       |
| 21         | 80  | F   | 24 h                        | Oxford-AstraZeneca | 2nd    | Giant seborrheic keratosis | None reported | Noncorrelated                       |

**FIGURE 1** Severe diffuse bullous erythema multiforme with rapidly occurring and evolving intensly red, round macules and papules, widely coalescing into large plaques and developing epidermal blistering.

**FIGURE 2** Urticarial reaction of the upper limbs and chest, characterized by small wheals with an erythematous rim and a pale center.
All HZ cases reported in literature, following COVID-19 vaccination, and our three cases, were moderate-to-mild cases and were successfully treated with antiviral therapy.8,16–18

Though the precise mechanisms involved in HZ development following COVID-19 vaccinations are still unknown, the increasing reports of HZ reactivation after mRNA-based and adenovirus-based COVID-19 vaccine call upon further studies.8,17–20

Also, Pityriasis rosea (PR) (-like) eruptions have been described after COVID-19 vaccination. These may be secondary to a T-cell-mediated response, triggered by molecular mimicry from a viral epitope, or secondary to endogenous systemic reactivation of human herpes virus (HHV)-6 and/or HHV-7.19–24 Of note, PR eruptions have been already described following other types of vaccinations, such as influenza vaccination with detection of HHV-6 and HHV-7 in skin biopsies.19–23

In our patient it occurred 30 days from the second dose of BioNTech/Pfizer and lasted approximately 35 days.

Interestingly, three patients presented exacerbation of their cutaneous diseases, including a flare of lichen planus, psoriasis and sarcoidosis, already present, and worsened, possibly induced by the vaccine.25

Last, three patients presented lesions that were discarded as not related to vaccination.

Indeed, seborrheic keratosis, eruptive angiomas, acral ecchymoses were interpreted as likely unrelated to the COVID-19 vaccination and no literature reports were found to support possible causal associations.25

5 | CONCLUSION

Despite the limitations of its descriptive and retrospective design, our study reports that cutaneous reactions to vaccination do not represent a contraindication to undergo COVID-19 vaccination. These data are in line with the literature so far collected, although we did not record in our patients the most common reported reactions in the literature following COVID-19 vaccines, i.e., local (early- or late-onset) reactions and chilblain-like lesions. This could possibly be the result of a selection bias, as the present study retrospectively assessed patients admitted at the Dermatology Primary Care.

Of note, cutaneous reactions considered worrisome by patients are mostly only mild or moderate, or not even associated with COVID-19 vaccination, possibly suggesting patients are just apprehensive about anything they note after vaccination.

However, awareness must be raised to recognize and treat eventual severe reactions. As worldwide vaccination efforts are being adopted against COVID-19, it is important for healthcare providers to recognize possible adverse events.
FUNDING INFORMATION

Funding information is not available.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

Martina Burlando, Astrid Herzum, and Claudia Micalizzi: performed the research. Martina Burlando, Astrid Herzum, Claudia Micalizzi, Emanuele Cozzani, and Aurora Parodi: designed the research study and revised the final version of the paper. Martina Burlando, Astrid Herzum, and Emanuele Cozzani: analyzed the data and wrote the paper. All authors have read and approved the final manuscript.

ORCID

Astrid Herzum https://orcid.org/0000-0001-6373-8801
Emanuele Cozzani https://orcid.org/0000-0003-3108-4123

REFERENCES

1. CDC COVID-19 Response Team. Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:46-51. doi:10.15585/mmwr.mm7002e1
2. Chung EH. Vaccine allergies. Clin Exp Vaccine Res. 2014;3:50-57. doi:10.7774/cevr.2014.3.1.50
3. Burlando M, Herzum A, Cozzani E, Parodi A. Acute urticarial rash after COVID-19 vaccination containing Polysorbate 80. Clin Exp Vaccine Res. 2021;10:298-300. doi:10.7774/cevr.2021.10.3.298
4. Herzum A, Burlando M, Molle MF, et al. Lichen planus flare following COVID-19 vaccination: a case report. Clin Case Rep. 2021:e5092. doi:10.1002/ccr3.5092
5. Kim MA, Lee YW, Kim SR, et al. COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group. Allergy Asthma Immunol Res. 2021;13:526-544. doi:10.4168/aaair.2021.13.4.526
6. Kounis NG, Koniali I, de Gregorio C, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines (Basel). 2021;9:221. doi:10.3390/vaccines9030221
7. Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9:1423-1437. doi:10.1016/j.jaip.2020.12.047
8. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85:46-55. doi:10.1016/j.jaad.2021.03.092
9. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Centers for Disease Control and Prevention. Accessed July 25, 2021. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html
10. Johnston MS, Galan A, Watsky KL, Little AJ. Delayed localized hypersensitivity reactions to the moderna COVID-19 vaccine: a case series. JAMA Dermatol. 2021;157:716-720. doi:10.1001/jamadermatol.2021.1214
11. Jedlowski PM, Jedlowski MF. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine. Dermatol Online J. 2021;27(1). doi:10.5070/D3271052044
12. Mahmood F, Muntyanu A, Besner Morin C, Litvinov I, Isabwe GAC, Netchiporouk E. Delayed cutaneous reactivity associated with COVID-19 vaccines is rare. J Cutan Med Surg. 2021;25(5):557-559. doi:10.1177/12034754211027854
13. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of BioNTech COVID-19 vaccine: is it a possible adverse effect? Clin Exp Dermatol. 2021;46:1325-1327. doi:10.1111/ced.14714
14. Ghimire K, Adhikari N. Morbilliform rashes in a patient with COVID-19 infection: a case report. J Cutan Med Surg. 2021;9:572. doi:10.3390/vaccines9060572
15. Aksu SB, Öztürk GZ. A rare case of shingles after COVID-19 vaccination: a case report. JAAD Case Rep. 2021;7:298-302. doi:10.1093/qjmed/hcab208
16. McManus DP, Amerson E, Rosenbach M, et al. Cutaneous reactions associated with COVID-19 vaccines is rare. JAMA Dermatol. 2021;157:716-720. doi:10.1001/jamadermatol.2021.1214
17. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of BioNTech COVID-19 vaccine: is it a possible adverse effect? Clin Exp Dermatol. 2021;46:1325-1327. doi:10.1111/ced.14714
18. Chiu HH, Wei KC, Chen A, Wang WH. Herpes zoster following COVID-19 vaccine: report of 3 cases. QJM. 2021;114:531-532. doi:10.1093/qjmed/hcab208
19. Cyrenne BM, Al Jallergy C. An Atypical case of pityriasis rosea in a patient with retrovirus infection: a reply. JAAD Case Rep. 2020;6:119-123.
20. Drago F, Herzum A, Ciccarese G, Broccolo F, Rebora A, Parodi A. Acute pain and postherpetic neuralgia related to Varicella zoster virus reactivation: comparison between typical herpes zoster and zoster sine herpete. J Med Virol. 2019;91:287-295. doi:10.1002/jmv.25304
21. Papakostas D, Stavropoulos PG, Papafragkaki D, Grigoriak E, Avgireniou G, Antoniou C. An Atypical case of pityriasis rosea gigantea after influenza vaccination. Case Rep Dermatol Venereol. 2021;13:546. doi:10.1111/jdv.17342
22. Drago F, Ciccarese G, Parodi A. Pityriasis rosea like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. J Eur Acad Dermatol Venereol. 2021;13:546. doi:10.1111/jdv.17342
23. Drago F, Ciccarese G, Parodi A. Pityriasis rosea like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. J Eur Acad Dermatol Venereol. 2021;13:546. doi:10.1111/jdv.17342
24. Rebora A, Ciccarese G, Herzum A, Parodi A, Drago F. Pityriasis rosea and other infectious eruptions during pregnancy: possible life-threatening health conditions for the fetus. *Clin Dermatol*. 2020;38(1):105-112.

25. Bauckneht M, Aloè T, Tagliabue E, et al. Beyond Covid-19 vaccination-associated pitfalls on [18F]Fluorodeoxyglucose (FDG) PET: a case of a concomitant sarcoidosis. *Eur J Nucl Med Mol Imaging*. 2021;48:482661-482662. doi:10.1007/s00259-021-05360-w

**How to cite this article:** Burlando M, Herzum A, Micalizzi C, Cozzani E, Parodi A. Cutaneous reactions to COVID-19 vaccine at the Dermatology Primary Care. *Immun Inflamm Dis*. 2022;10:265-271. doi:10.1002/iid3.568